Douglas Pharmaceuticals hail ‘breakthrough’ for treatment-resistant depression

+News

Douglas Pharmaceuticals hail ‘breakthrough’ for treatment-resistant depression

Jonathan
Chilton-Towle
depression_anxiety Photo by Nik Shuliahin on Unsplash
The early phase of the Douglas study saw 234 patients with treatment-resistant depression being given extended-release oral doses of ketamine [photo: Nik Shuliahin on Unsplash]
Douglas Pharmaceuticals is heralding early results of its trial on using ketamine to treat depression as possibly the most significant step in the fie